Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

[MicroRNA-146a polymorphism and susceptibility to gastrointestinal cancer: a meta-analysis]

Xiaohui Xu1, Yiqiang Zhang, Qingjun Lei

  • 1Depatment of General Surgery, The First People's Hospital of Taicang City, Jiangsu Taicang 215400, China. wangyi_taicang1965@126.com.

Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery
|July 28, 2015
PubMed
Abstract

Insights

The microRNA (miR)-146a gene polymorphism, specifically the G allele, is linked to increased susceptibility to gastrointestinal cancers. This finding highlights miR-146a as a potential biomarker for gastrointestinal cancer risk.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Gastrointestinal cancers represent a significant global health burden.
  • MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
  • Genetic variations in miRNA genes, such as miR-146a, may influence cancer susceptibility.

Purpose of the Study:

  • To investigate the association between microRNA (miR)-146a gene polymorphisms and the risk of developing gastrointestinal cancer.
  • To evaluate the impact of specific miR-146a genotypes on susceptibility to gastric and colorectal cancers.

Main Methods:

  • A systematic literature search was conducted across multiple databases (PubMed, Medline, Ovid, CNKI) for relevant studies published between July 2010 and March 2014.
  • Meta-analysis was employed to assess the association between miR-146a gene polymorphisms and gastrointestinal cancer risk using various genetic models (allele, dominant, recessive, homozygote, heterozygote).
  • Study quality was assessed using the Modified Jadad quality score, and statistical analysis was performed using Stata 11.0.

Main Results:

  • The meta-analysis included 16 studies with 7090 cancer patients and 9928 healthy controls.
  • The G allele of miR-146a was significantly associated with increased susceptibility to both gastric and colorectal cancers.
  • Specific genotypes (e.g., GG homozygote, dominant model GC+GG) showed a higher risk for gastric and colorectal cancers, while some models (e.g., heterozygous GC) did not show significant associations.

Conclusions:

  • The miR-146a gene polymorphism is closely associated with an increased risk of gastrointestinal cancers.
  • The findings suggest that miR-146a polymorphisms may serve as a genetic marker for gastrointestinal cancer susceptibility.
  • Further research is warranted to elucidate the precise mechanisms underlying this association.

More Related Videos

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

6.3K
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.8K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.9K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116